Sangamo Therapeutics And Chroma Medicine Announce Option And License Agreement To Evaluate And Develop Zinc Finger Proteins For Epigenetic Editing
Portfolio Pulse from Benzinga Newsdesk
Sangamo Therapeutics and Chroma Medicine have announced an option and license agreement to evaluate and develop Zinc Finger Proteins for Epigenetic Editing.
July 20, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sangamo Therapeutics has entered into a partnership with Chroma Medicine to develop Zinc Finger Proteins for Epigenetic Editing. This could potentially lead to new product developments and revenue streams for Sangamo.
The partnership with Chroma Medicine could potentially lead to the development of new products for Sangamo Therapeutics. This could open up new revenue streams and increase the company's market share in the biotech industry. Therefore, this news is likely to have a positive impact on Sangamo's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100